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OBJECTIVE: The IDNT trial demonstrated that irbe-
sartan slows progression to end-stage renal disease
(ESRD) in patients with type 2 diabetes compared to am-
lodipine and control, defined as placebo in addition to
other antihypertensive therapies. Treatment of ESRD is
very expensive, costing  $50,000 USD/year/patient, and
diabetes is the most common underlying etiology. The
purpose of this analysis was to estimate the economic im-
pact of irbesartan in this population of patients.
METHODS: For the economic analysis, study endpoints
were defined as ESRD or imputed ESRD derived from the
observation of a doubling of serum creatinine (DSC),
which has been shown to predict ESRD. For the imputed
estimate, we applied the observed median follow-up time
between DSC and ESRD to impute time to ESRD in pa-
tients who experienced DSC without ESRD. Kaplan-
Meier survival estimation was then applied to these data
stratified by treatment. The difference in cumulative inci-
dence rates at three years was used to assess the absolute
risk reduction (ARR) in averting ESRD between treat-
ment arms. The ARR was used to calculate the number
of ESRD events averted. Using data from the NHANES
III survey, we then estimated the number of IDNT-eligi-
ble patients in the US. Based on the year 2000 Annual
Data Report for the United States Renal Data System, a
yearly ESRD cost/patient of $52,649 was utilized.
RESULTS: We estimated the ARR for our endpoint to be
6.4% at three years for irbesartan versus control. Approx-
imately 550,000 NHANES III subjects met the IDNT eligi-
bility criteria. Compared to control, irbesartan treatment
would prevent approximately 35,000 cases of ESRD, at
cost savings of 2.5 billion dollars over three years.
CONCLUSION: Treatment of IDNT-eligible patients
with irbesartan has the potential of generating large sav-
ings for the US health-care system.
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OBJECTIVES: This study examines factors associated
with drug treatment changes after an HbA1c test in a pri-
vately insured sample of diabetes patients in Califor-
nia, USA.
METHODS: Diabetes patients were selected from a phy-
sician organization with approximately 1600 physicians
and 220,000 patients. Electronic records of HbA1c test
results, prescriptions, inpatient and outpatient visits, and
enrollment periods from 1/1/1997 through 9/30/2000
were collected for patients enrolled in two affiliated
Health Maintenance Organizations. Patients in the final
sample had at least one HbA1c test result and were en-
rolled for 120 days after (observation period) and 12
months before (baseline period) their most recent test.
Diabetes comorbidities, drug class, and therapy days (a
proxy for compliance/persistence) were determined for
the baseline period. A logistic regression tested whether
these factors or patient demographics were associated
with addition or discontinuation of diabetes drug classes
following the test.
RESULTS: Of the 7104 diabetes patients in the database,
2643 (37.2%) met all criteria for the final sample. Mean age
was 64.6 years (SD  14.3), and 49.9% of the population
was female. Patients’ baseline period drug treatments in-
cluded insulin alone (n  246, 9.3%), sulfonylureas alone
(n  649, 24.6%), metformin alone (n  195, 7.4%), sulf-
met combination (n  536, 20.3%), other multiple (n 
233, 8.8%) and no therapy (n  784, 29.7%). Overall, 599
(22.6%) patients changed treatments. Higher HbA1c levels
predicted increased rates of treatment change (Odds Ratio
[OR]1.22 per 1-point HbA1c difference, p  .0001). Rel-
ative to patients with no drug treatment, patients receiving
oral drug treatment were more likely to change treatments
(OR range 14.4–33.1, all p  .0001). Compliance/persis-
tence with oral treatments during the baseline period pre-
dicted a lower rate of treatment changes (OR range 0.04–
0.09, all p  .0004).
CONCLUSIONS: Patients with higher HbA1c test re-
sults are more likely to change drug treatment, suggesting
appropriate physician responses to inadequate glycemic
control. Compliance/persistence appears to affect the de-
cision to change oral treatments.
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OBJECTIVE: Diabetes mellitus affects over 600,000 peo-
ple in the Czech republic. The treatment algorithms for
diabetic patients currently used in the Czech Republic are
in agreement with the international recommendations.
We compared data on consumption of antidiabetics (in-
sulin and oral antidiabetics) in the Czech republic with
that in other countries.
METHODS: Data on insulin and oral antidiabetic drug
consumption were expressed in terms of defined daily
doses per 1000 inhabitants per day (i.e. DDD/1000 inh/d).
RESULTS: Insulin consumption is slowly increasing. Con-
sumption of sulphonylureas is slowly decreasing while
that of biguanides is increasing. The proportion of met-
formin use is more than 50% above that of biguanides.
CONCLUSION: It follows from the present comparisons,
